GIANT BIOGENE (02367) Wholly-Owned Subsidiary Receives NMPA Medical Device Registration Certificate for Recombinant Type I α1 Collagen and Sodium Hyaluronate Compound Solution

Stock News01-15

GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has received a Medical Device Registration Certificate (Registration Certificate No.: 国械注准20263130044) from the National Medical Products Administration (NMPA) for its recombinant Type I α1 collagen and sodium hyaluronate compound solution product.

This product, which uses recombinant collagen and sodium hyaluronate as its primary components, is intended for injection into the dermis to improve cheek smoothness.

It is the world's first recombinant collagen and sodium hyaluronate compound solution implant approved through a combined device and pharmaceutical review process for improving cheek smoothness.

Following the successful approval of the recombinant Type I α1 collagen lyophilized fiber, this new product further expands the company's product portfolio, showcasing the group's sustained leadership in technological R&D and industrial capabilities.

The approval also unlocks broader market potential, injecting new growth momentum into the company's business development in the skin rejuvenation field.

Moving forward, the company will steadily advance the market launch and promotion of this product, aiming to provide differentiated solutions for diverse consumer needs through its multi-product portfolio, comprehensive channel network, and sophisticated brand management.

These efforts will continue to strengthen the company's leading market position in the health and beauty sectors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132622255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132622255","market":"sh","top_or_hot":-1,"title":"GIANT BIOGENE (02367) Wholly-Owned Subsidiary Receives NMPA Medical Device Registration Certificate for Recombinant Type I α1 Collagen and Sodium Hyaluronate Compound Solution","media":"Stock News","content":"<p>GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has received a Medical Device Registration Certificate (Registration Certificate No.: 国械注准20263130044) from the National Medical Products Administration (NMPA) for its recombinant Type I α1 collagen and sodium hyaluronate compound solution product.</p>\n<p>This product, which uses recombinant collagen and sodium hyaluronate as its primary components, is intended for injection into the dermis to improve cheek smoothness.</p>\n<p>It is the world's first recombinant collagen and sodium hyaluronate compound solution implant approved through a combined device and pharmaceutical review process for improving cheek smoothness.</p>\n<p>Following the successful approval of the recombinant Type I α1 collagen lyophilized fiber, this new product further expands the company's product portfolio, showcasing the group's sustained leadership in technological R&D and industrial capabilities.</p>\n<p>The approval also unlocks broader market potential, injecting new growth momentum into the company's business development in the skin rejuvenation field.</p>\n<p>Moving forward, the company will steadily advance the market launch and promotion of this product, aiming to provide differentiated solutions for diverse consumer needs through its multi-product portfolio, comprehensive channel network, and sophisticated brand management.</p>\n<p>These efforts will continue to strengthen the company's leading market position in the health and beauty sectors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GIANT BIOGENE (02367) Wholly-Owned Subsidiary Receives NMPA Medical Device Registration Certificate for Recombinant Type I α1 Collagen and Sodium Hyaluronate Compound Solution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGIANT BIOGENE (02367) Wholly-Owned Subsidiary Receives NMPA Medical Device Registration Certificate for Recombinant Type I α1 Collagen and Sodium Hyaluronate Compound Solution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-15 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has received a Medical Device Registration Certificate (Registration Certificate No.: 国械注准20263130044) from the National Medical Products Administration (NMPA) for its recombinant Type I α1 collagen and sodium hyaluronate compound solution product.</p>\n<p>This product, which uses recombinant collagen and sodium hyaluronate as its primary components, is intended for injection into the dermis to improve cheek smoothness.</p>\n<p>It is the world's first recombinant collagen and sodium hyaluronate compound solution implant approved through a combined device and pharmaceutical review process for improving cheek smoothness.</p>\n<p>Following the successful approval of the recombinant Type I α1 collagen lyophilized fiber, this new product further expands the company's product portfolio, showcasing the group's sustained leadership in technological R&D and industrial capabilities.</p>\n<p>The approval also unlocks broader market potential, injecting new growth momentum into the company's business development in the skin rejuvenation field.</p>\n<p>Moving forward, the company will steadily advance the market launch and promotion of this product, aiming to provide differentiated solutions for diverse consumer needs through its multi-product portfolio, comprehensive channel network, and sophisticated brand management.</p>\n<p>These efforts will continue to strengthen the company's leading market position in the health and beauty sectors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1132622255","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132622255","pubTimestamp":1768468719,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has received a Medical Device Registration Certificate (Registration Certificate No.:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159883":"医疗器械","02367":"巨子生物","BK1100":"医疗保健设备","BK1207":"个人用品","BK1222":"医疗保健用品","BK1574":"生物医药B类股","09996":"沛嘉医疗-B","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","09997":"康基医疗","BK1583":"高瓴概念"},"translate_title":"巨人生物(02367)全资附属公司获NMPA医疗器械注册证重组I型α 1胶原及透明质酸钠复方溶液","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1,"02367":1,"09997":1,"09996":1},"content_text":"GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has received a Medical Device Registration Certificate (Registration Certificate No.: 国械注准20263130044) from the National Medical Products Administration (NMPA) for its recombinant Type I α1 collagen and sodium hyaluronate compound solution product.\nThis product, which uses recombinant collagen and sodium hyaluronate as its primary components, is intended for injection into the dermis to improve cheek smoothness.\nIt is the world's first recombinant collagen and sodium hyaluronate compound solution implant approved through a combined device and pharmaceutical review process for improving cheek smoothness.\nFollowing the successful approval of the recombinant Type I α1 collagen lyophilized fiber, this new product further expands the company's product portfolio, showcasing the group's sustained leadership in technological R&D and industrial capabilities.\nThe approval also unlocks broader market potential, injecting new growth momentum into the company's business development in the skin rejuvenation field.\nMoving forward, the company will steadily advance the market launch and promotion of this product, aiming to provide differentiated solutions for diverse consumer needs through its multi-product portfolio, comprehensive channel network, and sophisticated brand management.\nThese efforts will continue to strengthen the company's leading market position in the health and beauty sectors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132622255","isCrawlerRequest":true}